{"id":834386,"date":"2025-04-07T08:06:36","date_gmt":"2025-04-07T12:06:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/"},"modified":"2025-04-07T08:06:36","modified_gmt":"2025-04-07T12:06:36","slug":"dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/","title":{"rendered":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:center\">\n          <strong><br \/>\n            <em>Dar\u00e9 unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from women<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:center\">\n          <strong><br \/>\n            <em>Dar\u00e9 is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">SAN DIEGO, April  07, 2025  (GLOBE NEWSWIRE) &#8212; Dare\u0301\u00a0Bioscience, Inc.\u00a0(NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women&#8217;s health a priority, today announced that Sabrina Martucci Johnson, the company\u2019s President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company\u2019s expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Dar\u00e9 proprietary formulations to market as soon as practicable, starting with its proprietary Sildenafil Cream formulation this year. There are other proprietary formulations in the Dar\u00e9 portfolio that could also be provided via a prescription through the Section 503B of the FDCA framework.<\/p>\n<p align=\"justify\">\u201cWe are actively evaluating a dual-path approach for some of the other proprietary formulations as part of our responsibility to women, to the healthcare community, and to our shareholders. In addition, we may also bring to market consumer health products that can be obtained without a physician\u2019s prescription. We are targeting this quarter to provide an update on timing and strategic partnerships to achieve these objectives, and I look forward to discussing our previously announced expanded business strategy this Wednesday, April 9<sup>th<\/sup>,\u201d said Ms. Johnson.<\/p>\n<p align=\"justify\">The live presentation may be accessed via webcast. Details for the presentation are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: top\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%;vertical-align: top\">Jones Healthcare and Technology Innovation Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Date \/ Time:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">Wednesday, April 9, 2025, 1:00 p.m. PT\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Webcast Link:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/wsw.com\/webcast\/jones2\/dare\/1859132\" rel=\"nofollow\" target=\"_blank\">https:\/\/wsw.com\/webcast\/jones2\/dare\/1859132<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"vertical-align: top\">A replay of the presentation will be available in the Investors section of the company&#8217;s website at <a href=\"http:\/\/ir.darebioscience.com\" rel=\"nofollow\" target=\"_blank\">http:\/\/ir.darebioscience.com<\/a> under \u201cPresentations, Events &amp; Webcasts\u201d until April 23, 2025.<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Dar\u00e9 Bioscience<\/strong><br \/>\n        <br \/>Dar\u00e9 Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women&#8217;s health a priority. We believe that innovation does not have to start from scratch. Our goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women\u2019s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products we identify, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that we leverage. This gives us optionality and flexibility, in many cases, in how we seek to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner.<\/p>\n<p align=\"justify\">The first FDA-approved product to emerge from Dar\u00e9\u2019s portfolio of women\u2019s health product candidates is XACIATO\u2122 (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MhK17Tqe6XTvSrBkKpikDtZ48733TBFVHyQBp3YVOgGGwO28AqR1tAPDL_JcurJq0UEINeUuKwxccxvMT7eODaOWK18f2slUgkJktMkNRNc4wv6ILn2lrBapOSHDOYqrCd6O-B6RMXdImgdEi02lvDlf90DjlQhpEJVo5oqCxKWuO4DLXDGcMPV-coH_Rwf0ZML69nv3R3RRJXkv9bO-U2Zan1dCbF7AuRuiUEWLhKc=\" rel=\"nofollow\" target=\"_blank\"><u>www.xaciato.com<\/u><\/a>\u00a0for information about XACIATO. Dar\u00e9\u2019s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene<sup>\u00ae<\/sup>, a novel, hormone-free monthly intravaginal contraceptive whose\u00a0U.S.\u00a0commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra<sup>\u00ae<\/sup>, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Dar\u00e9\u2019s full portfolio of women\u2019s health product candidates and mission to deliver differentiated therapies for women, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6THoojEm6wF7dGTEm6xENif8pBEGY65tFEs8ltRq8zFcPle8bQilAdV5w1Xp1rcfLzMtqXZ131yHyrW71wYr7AlE6-UiIfjnOu8s1JSc4laZWsc2UTM3sBDh4arkuLDESFDl4cFOGYLs91NZdE34WYXb66w44Azkuuu9V0F_ygkjVw96CZ2DYk4ZeR7qismYbG73hnwdWmjlzlOnjr05SZCFssQ-M5k9uv-gIS2xmaz_5pIKyB4GvR-TgAHTlNYycOdlnHPw-lbBFhazLsMRJg==\" rel=\"nofollow\" target=\"_blank\"><u>www.darebioscience.com<\/u><\/a>.<\/p>\n<p align=\"justify\">Dar\u00e9 Bioscience leadership has been named on the Medicine Maker\u2019s Power List and Endpoints News\u2019 Women in Biopharma and Dar\u00e9&#8217;s CEO has been honored as one of Fierce Pharma\u2019s Most Influential People in Biopharma for Dar\u00e9\u2019s contributions to innovation and advocacy in the women\u2019s health space.<\/p>\n<p align=\"justify\">Dar\u00e9 may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8c0EU9f-tFftJb0vP_WALTO0Hkihid8QDqZUTa7aFJA-TgUHzM-gp7FfIQs8d5YoHiu6cI3KxZOtDNx-hnTvoMYGvq4fOMEe7fEs6hp9BlBHw9DRC-LVKmyKiaOyMSPs0JjibPUbnWFhEhp71Ojbwvneod6wiH57OAuwERpZCiwp1o-Iqe688mu7zzSDixnheT5RpbapWLxxShEnhxNhHvkS13uo4TPcHuttdLZd_-qC_E8Nfx0fR7AHd-dMBrQQ8zPevo1AYzmUsUVmcZAQeAYaIMigy02ohnEqJzCr_H6pkUrYtmrpwygwmCwUIoME\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/ir.darebioscience.com<\/u><\/a>),\u00a0SEC\u00a0filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dar\u00e9\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Dar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cobjective,\u201d \u201con track,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to plans and expectations with respect to Dar\u00e9\u2019s product candidates; Dar\u00e9\u2019s plans and timing for making its proprietary formulation of Sildenafil Cream available by prescription in the U.S. as a compounded drug via Section 503B of Federal Food, Drug, and Cosmetic Act (FDCA); its anticipated market acceptance and potential market demand; the potential for Dar\u00e9 to take action to make other proprietary formulations in the Dar\u00e9 portfolio available as compounded drugs via Section 503B of the FDCA; the potential for Dar\u00e9 to bring to market consumer health products; and potential third-party collaborations. As used in this press release, \u201cfirst-in-category\u201d is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Dar\u00e9 believes it would address a need in women\u2019s health that is not being met by existing FDA-approved products. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Dar\u00e9\u2019s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; the risk of delisting of Dar\u00e9\u2019s common stock from Nasdaq; developments impacting U.S. federal government contracting and funding of research and development activities; the degree of market demand and acceptance for Dar\u00e9\u2019s proprietary formulation of Sildenafil Cream provided as a compounded drug; the performance of Section 503B-registered outsourcing facilities on which Dar\u00e9 will rely; the risk that the FDA could stop permitting Section 503B-registered outsourcing facilities to compound sildenafil citrate or other active pharmaceutical ingredients in the company\u2019s proprietary formulations that it is evaluating making available via Section 503B of the FDCA; Dar\u00e9\u2019s ability to achieve the product development and other milestones required for it to receive payments under its subaward and grant agreements; the limits on Dar\u00e9\u2019s ability to sell stock under its equity line arrangement at times it may desire to raise additional capital; Dar\u00e9\u2019s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; Dar\u00e9\u2019s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Dar\u00e9\u2019s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risk that positive findings in early clinical and\/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar\u00e9\u2019s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Dar\u00e9 anticipates; the risk that the current regulatory pathway known as the FDA\u2019s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Dar\u00e9 anticipates; the loss of, or inability to attract, key personnel; the effects of macroeconomic conditions, geopolitical events, public health emergencies, and major disruptions in government operations on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that developments by competitors make Dar\u00e9\u2019s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and\/or commercial collaborators; failure of Dar\u00e9\u2019s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Dar\u00e9\u2019s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9\u2019s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Dar\u00e9\u2019s or its licensors\u2019 failure to obtain and maintain sufficient intellectual property protection; the lack of patent protection for the active ingredients in certain of Dar\u00e9\u2019s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Dar\u00e9\u2019s product or product candidates or the business activities of Dar\u00e9, its commercial collaborators or other third parties on which Dar\u00e9 relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events that compromise Dar\u00e9\u2019s technology systems or those of third parties on which it relies and\/or significantly disrupt Dar\u00e9\u2019s business; and disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Dar\u00e9 Bioscience Investor Relations<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ki2H6xVTfxz62RvUJxb8oEmfI7WLJrB-mot-WUw8O2YNwHL0ELb9KBlsUOpWFCIlAQw9V7C_ccQSUVJ385JSP-H7_7pcA2eYoEVuPMSokuTKyg_WvvtKzNksQUQJNPO6zPcWQwBqixPfp_-fhil5fdpVal6_pZo3lqKaXvQxVbDqOAVwDZE4mWKyxA6ErA5phwCTrSwXvWpd-KdPanO-yo2huQP-HqMXxKkmAPXh7zHJrDJbV0cCfgo0ttNmgevvRRTACt0gUTLHfiuCXQQLJQC2ktXSOmuwLgoLRwCGnM8Xj6M0v_r42HLM1MUW-qpMpiZTysHOc6VPz2XSPOLuENsd9JlP9ECYa4S_-dz7sJhjtRmxhW1rA1BNXUpvqh8Urjn0C5PijyYYaIoN0DOeBKIWg4nBJK4EoUcywcghtsnlE1uHlqAhL-LFKd2n5z6l2Bvrecm1vOzYb-mbm-XR8VL9carhag5dlcR4ffvFXnEJcg8ypAobR61AH8gEoHBxJUYUuv8ZloGbMFq_f-UU9eafqN9WR6vcrGVLD7ETH8Jk9ibrgeHtykGXBYUAJPkQ\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>innovations@darebioscience.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>Source: Dar\u00e9\u00a0Bioscience, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTIwNDk2NGItNjE4Zi00YTk1LTg3YjQtNDllNDY0NWRiZWM5LTEwMTk5MzctMjAyNS0wNC0wNy1lbg==\/tiny\/Dar-Bioscience-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dar\u00e9 unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from women Dar\u00e9 is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301\u00a0Bioscience, Inc.\u00a0(NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women&#8217;s health a priority, today announced that Sabrina Martucci Johnson, the company\u2019s President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company\u2019s expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Dar\u00e9 proprietary formulations to market as soon as practicable, starting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834386","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dar\u00e9 unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from women Dar\u00e9 is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301\u00a0Bioscience, Inc.\u00a0(NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women&#8217;s health a priority, today announced that Sabrina Martucci Johnson, the company\u2019s President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company\u2019s expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Dar\u00e9 proprietary formulations to market as soon as practicable, starting &hellip; Continue reading &quot;Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T12:06:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year\",\"datePublished\":\"2025-04-07T12:06:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/\"},\"wordCount\":1922,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/\",\"name\":\"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\",\"datePublished\":\"2025-04-07T12:06:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/","og_locale":"en_US","og_type":"article","og_title":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk","og_description":"Dar\u00e9 unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from women Dar\u00e9 is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301\u00a0Bioscience, Inc.\u00a0(NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women&#8217;s health a priority, today announced that Sabrina Martucci Johnson, the company\u2019s President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company\u2019s expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Dar\u00e9 proprietary formulations to market as soon as practicable, starting &hellip; Continue reading \"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-07T12:06:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year","datePublished":"2025-04-07T12:06:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/"},"wordCount":1922,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/","name":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=","datePublished":"2025-04-07T12:06:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzc0OCM2ODUzNDA0IzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-present-at-the-jones-healthcare-and-technology-innovation-conference-on-expanded-business-strategy-including-action-to-make-its-proprietary-sildenafil-cream-formulation-available-vi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dar\u00e9 Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834386"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}